HydrAMP generates antimicrobial peptide analogues validated in bacterial assays
HydrAMP, a conditional variational autoencoder with antimicrobial activity classifiers, generated peptide analogues and de novo candidates. The 2022 preprint reports wet-lab confirmation of increased activity for a generated Pexiganan-based analogue; the 2023 journal version reports testing across five bacterial strains, including nine analogues of clinical prototypes and six analogues of an inactive peptide. The tested panel was small and model/human filtered; it does not establish therapeutic efficacy.
Technology: Conditional variational autoencoder with classifier-guided peptide generation and molecular-dynamics-based candidate preselection
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Generated peptide analogues were experimentally evaluated for antimicrobial activity across five bacterial strains; the journal abstract reports high activity for nine generated analogues of clinical prototypes and six analogues of an inactive peptide.
- Still unknown: The tested panel is selected and small; these are in-vitro assays and do not establish safety, therapeutic efficacy or clinical benefit. The 2023 correction replaced a duplicated generation-statistics figure, not the wet-lab result stated here.
- AI role: A conditional VAE generated peptide analogues and unconstrained candidates from antimicrobial activity conditions; ranking and molecular-dynamics preselection helped choose candidates for experimental validation.
Evidence sources: https://www.biorxiv.org/content/10.1101/2022.01.27.478054v1 · https://www.nature.com/articles/s41467-023-36994-z · https://www.nature.com/articles/s41467-023-40879-6.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv v1 abstract/metadata; primary Nature Communications indexed full article including methods/results; primary publisher author correction..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.